Review articlePyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease☆
References (78)
Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators
Baillière's Clin Haematol
(1994)- et al.
Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine
Lancet
(1979) - et al.
Mobilization of iron from reticulocytes
- et al.
A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents
Biochim Biophys Acta
(1979) - et al.
Iron chelation therapy and the treatment of thalassemia
Blood
(1997) - et al.
The effectiveness of deferiprone in thalassemia
Blood
(1997) - et al.
Oral iron chelation with deferiprone
Pediatr Clin North Am
(1997) - et al.
Mode of action of iron(III) chelators as anti-malarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives
J Lab Clin Med
(1996) - et al.
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents
Blood
(1995) - et al.
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents II. The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-l-naphthylaldehyde benzoyl hydrazone
Blood
(1997)
Structural studies of Fe(III) and Cu(II) complexes of salicylaldehyde benzoyl hydrazone, a synthetic chelating agent exhibiting diverse biological properties
Inorganica Chim Acta
(1982)
Structural studies of iron(III) complexes of the new iron-binding drug pyridoxal isonicotinoyl hydrazone
Inorg Chim Acta
(1982)
Iron chelators of the pyridoxal isonicotinoyl hydrazone class part 1. Ionisation characteristics of the ligands and their relevance to biological properties
Inorganica Chim Acta
(1990)
Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture
Biochem Pharmacol
(1985)
The release of iron and transferrin from the human melanoma cell
Biochim Biophys Acta
(1991)
A study of the mechanism of action of pyridoxal isonicotinoyl hydrazone at the cellular level using reticulocytes loaded with non-heme 59Fe
Biochim Biophys Acta
(1983)
Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process
Biochim Biophys Acta
(1997)
Iron utilization in rabbit reticulocytes
The effects of inhibition of heme synthesis on the intracellular localisation of iron in rat reticulocytes
Biochim Biophys Acta
(1989)
Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates of iron metabolism
Blood
(1996)
Chelator-mediated iron efflux from reticulocytes
Biochim Biophys Acta
(1983)
The pharmacokinetics and blood brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat
Toxicology
(1996)
Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes
Biochim Biophys Acta
(1988)
Release of iron from endosomes is an early step in the transferrin cycle
Int J Biochem
(1987)
Potential protection from toxicity by oral iron chelators
Toxicol Lett
(1995)
The clinical approach to thalassemia
(1984)
Continuous subcutaneous administration of desferrioxamine in patients with iron overload
N Engl J Med
(1977)
Randomized trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major [abstract]
Blood
(1996)
Long-term follow-up of body iron in patients with thalassemia major during therapy with the orally active iron chelator deferiprone (L1) [abstract]
Blood
(1996)
Oral iron chelators may do more harm than good
Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators
Br J Haematol
(1995)
Deferiprone-associated myelotoxicity
Eur J Haematol
(1994)
Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial
Ann Hematol
(1996)
Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone)
Br J Haematol
(1997)
The design of orally active iron chelators for the treatment of thalassemia
Iron chelation therapy with oral deferiprone in patients with thalassemia major
N Engl J Med
(1995)
In vitro anti-oxidant properties of the iron chelator pyridoxal isonicotinoyl hydrazone and some of its analogs
Redox Report
(1996)
The potential of iron chelators as effective antiproliferative agents
Can J Physiol Pharmacol
(1997)
Cited by (129)
The thiosemicarbazone, DpC, broadly synergizes with multiple anti-cancer therapeutics and demonstrates temperature- and energy-dependent uptake by tumor cells
2022, Biochimica et Biophysica Acta - General SubjectsThe Use of Hydrazones for Biomedical Applications
2019, SLAS TechnologyModifying aroylhydrazone prochelators for hydrolytic stability and improved cytoprotection against oxidative stress
2018, Bioorganic and Medicinal ChemistryThe interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) with iron
2018, Journal of Inorganic Biochemistry
- ☆
Supported by operating grants from the Medical Research Council of Canada (D.R.R. and PP.), a Terry Fox New Investigator Award from the National Cancer Institute of Canada (D.R.R.), and the National Health and Medical Research Council of Australia (D.R.R). D.R.R. was the recipient of a Medical Research Council of Canada Scholarship.
Copyright © 1998 Published by Mosby, Inc.